<DOC>
	<DOCNO>NCT02100761</DOCNO>
	<brief_summary>To investigate relationship cytochrome P450 ( CYP ) 2C19 genetic polymorphism steady-state blood concentration voriconazole Chinese patient invasive pulmonary aspergillosis ( IPA ) , assess effect voriconazole trough concentration prognosis IPA patient .</brief_summary>
	<brief_title>CYP 2C19 Polymorphism Voriconazole Trough Concentration Chinese Adult Patients</brief_title>
	<detailed_description>Each isolate aspergillosis recover clinical specimen ( sputum , bronchoalveolar lavage fluid , lung biopsy tissue ) identification specie level also perform Qilu Hospital use conventional method ( macroscopic microscopic characteristic ) . The aspergillosis strain store 10 % glycerol broth -80 °C . The vitro antifungal susceptibility test aspergillosis strain voriconazole perform Centre Medical Mycology Mycoses , First Hospital , Peking University , performance accord Clinical Laboratory Standards Institute ( CLSI ) standard M38-A2 microdilution method . Serum galactomannan ( GM ) test perform twice per week first two week . A double-sandwich ELISA GM assay use . A cut-off optical density index ( ODI ) &gt; 0.5 take positive . Voriconazole serum level measure day 4 , day 7 , day 10 , day 14 ( trough level ) . In brief , quantitative analysis voriconazole perform use high-performance liquid chromatography couple tandem mass spectrometry . Genotyping CYP2C19 perform use 3 ml peripheral blood sample EDTA ( ethylenediaminetetraacetic acid ) tube day 4 . Genomic DNA extract blood leukocyte use DNA extraction kit . Genotyping confirmed polymerase chain reaction ( PCR ) -restriction fragment length polymorphism ( RFLP ) analysis . Individuals divide three group accord CYP2C19 genotype . Those inherit two mutant CYP2C19 allele ( *2 and/or *3 ) reduce capacity metabolize CYP2C19 substrate define poor metabolizers ( PMs ) . Individuals homozygous ( *1/*1 ) wild-type CYP2C19*1 1 wild-type allele 1 CY¬P2C19*17 efficient enzyme metabolize CYP2C19 substrate define extensive metabolizers ( EMs ) . Subjects heterozygous ( *1/*2 , *1/*3 ) wild-type CYP2C19*1 define intermediate metabolizers ( IMs )</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Proven , probable , possible invasive pulmonary aspergillosis ( IPA ) Acute IPA define duration clinical syndrome &lt; 30 day . Treatment voriconazole At least 18 year old Weight &gt; 40 kg ≤120 kg Given inform consent Patients allergic azole ( ) Patients heve prescribe voriconazole Positive urine pregnancy test ( female ) Patients aspergilloma chronic aspergillosis ( &gt; 1 month duration ) Anticipated survival le 5 day Karnofsky score &lt; =20</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Invasive pulmonary aspergillosis</keyword>
	<keyword>Therapeutic drug monitoring</keyword>
	<keyword>CYP genetic polymorphism</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>